SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (19393)3/8/1999 11:01:00 PM
From: John M. Gelnieau  Respond to of 23519
 
Better read this! 'NEGOTIATIONS"

quote.bloomberg.com

Eight-year-old Vivus disclosed the patent as holds negotiations that could result in the company selling itself or signing an agreement with a big drugmaker to market Vivus's main product, the impotence treatment Muse. The drug's sales and Vivus shares tumbled last year after Pfizer Inc. introduced Viagra in one of the most successful new drug launches to date.



To: Mkilloran who wrote (19393)3/8/1999 11:04:00 PM
From: blankmind  Respond to of 23519
 
My prophesy from 8/98:

"- Shorters have won many battles but not the war
- Until the WSJ reports a short interest of less than 500,000 shares, the game isn't over.
- Here's one possible scenario:
a. 3rd 1/4 return to profitability
b. Marketing Partner in US - to radically cut costs - and add further profits
c. Short Covering & Institutional Buying, i.e. Paine Weber
- And stock price does a KTEL. -- who knows?"


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News